Form 4: Revolution Medicines' General Counsel Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Jeff Cislini, General Counsel of Revolution Medicines, sold 2,000 shares of common stock at an average price of $38.4698 on June 26, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On June 26, 2024, Jeff Cislini, the General Counsel of Revolution Medicines, sold 2,000 shares of the company's common stock.
- The sale was executed at a weighted average price of $38.4698 per share, with individual trades ranging from $38.11 to $38.80.
- The transaction was conducted under a pre-existing 10b5-1 trading plan adopted on March 20, 2024.
- Following the transaction, Cislini directly owns 49,487 shares of Revolution Medicines, including 44,217 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
Sales by company insiders are a normal part of corporate activity. The fact that this sale was conducted under a pre-arranged 10b5-1 trading plan suggests it was planned and not necessarily based on current market conditions or inside information.
Key Dates
| Date | Description |
|---|---|
| 2024/03/20 | Date of adoption of the 10b5-1 trading plan by the Reporting Person. |
| 2024/06/26 | Date of the transaction: sale of 2,000 shares of common stock. |
| 2024/06/27 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.